Literature DB >> 7308271

Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro.

M J Brodie, A R Boobis, C J Bulpitt, D S Davies.   

Abstract

The effects of liver disease and environmental factors on hepatic microsomal cytochrome P-450 content, NADPH-cytochrome c reductase (reductase) activity and aryl hydrocarbon hydroxylase (AHH) activity have been simultaneously investigated in 70 patients undergoing diagnostic liver biopsy. The activity of reductase was not significantly affected by the presence of liver disease or any of the environmental factors studied. Cytochrome P-450 content decreased with increasing severity of liver disease whereas AHH activity was only significantly reduced in biopsies showing hepatocellular destruction. None of the parameters of monooxygenase activity varied significantly with the age or sex of the patients. Alcohol excess was associated with decreased cytochrome P-450 content and AHH activity and this effect was independent of the histological status of the biopsy. Both high caffeine intake and cigarette smoking increased AHH activity in the absence of any change in cytochrome P-450 content. There was a positive correlation between the number of meat meals eaten per week and cytochrome P-450 content. Chronic treatment with enzyme-inducing anticonvulsants appeared to increase both cytochrome P-450 content and AHH activity. Despite differential effects of liver disease and environmental influences on cytochrome P-450 content and AHH activity there was a highly significant correlation between the two parameters. The results of the present study correlate well with the known effects of disease and environment on drug metabolism in vivo.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7308271     DOI: 10.1007/bf00554665

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  39 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Drug metabolism in malnourished children: a study with antipyrine.

Authors:  M Homeida; Z A Karrar; C J Roberts
Journal:  Arch Dis Child       Date:  1979-04       Impact factor: 3.791

3.  Effect of smoking on theophylline disposition.

Authors:  S N Hunt; W J Jusko; A M Yurchak
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

Review 4.  Drug disposition and liver disease.

Authors:  G R Wilkinson; S Schenker
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

5.  Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man.

Authors:  D S Davies; S S Thorgeirsson
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

6.  Drug metabolism in white vegetarians.

Authors:  M J Brodie; A R Boobis; E L Toverud; W Ellis; S Murray; C T Dollery; S Webster; R Harrison
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

7.  Monooxygenase enzyme activity in alcoholics with varying degrees of liver damage.

Authors:  H Hoensch; F Hartmann; H Schomerus; P Bieck; W Dölle
Journal:  Gut       Date:  1979-08       Impact factor: 23.059

8.  Reduction of circulating 25-hydroxyvitamin D by antipyrine.

Authors:  P F Wilmana; M J Brodie; J C Mucklow; H S Fraser; E L Toverud; D S Davies; C T Dollery; C J Hillyard; I Macintyre; B K Park
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

9.  Comparative metabolism of benzo[a]pyrene and drugs in human liver.

Authors:  J Kapitulnik; P J Popper; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875

10.  Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes.

Authors:  S A Atlas; E S Vesell; D W Nebert
Journal:  Cancer Res       Date:  1976-12       Impact factor: 12.701

View more
  16 in total

1.  Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity.

Authors:  H Kraul; J Truckenbrodt; A Huster; R Töpfer; A Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

3.  The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects.

Authors:  J Vincent; R Liminana; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

4.  The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.

Authors:  D G Le Couteur; A J McLean
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

5.  The 14C-aminophenazone breath test in pesticide workers.

Authors:  B Dietze; K O Haustein; G Hüller; C Brückner
Journal:  Int Arch Occup Environ Health       Date:  1986       Impact factor: 3.015

Review 6.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

7.  Conjugation pathways in liver disease.

Authors:  G M Pacifici; A Viani; M Franchi; S Santerini; A Temellini; L Giuliani; M Carrai
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

8.  Antipyrine elimination as a dynamic test of hepatic functional integrity in obstructive jaundice.

Authors:  G A McPherson; I S Benjamin; A R Boobis; M J Brodie; C Hampden; L H Blumgart
Journal:  Gut       Date:  1982-09       Impact factor: 23.059

9.  Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level.

Authors:  F Witassek; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  7-Ethoxyresorufin deethylase (EROD) in human liver--the effect of alcoholic liver disease.

Authors:  K W Woodhouse; E Mutch; F M Williams; O F James; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.